Top 10 Cleavable PEG Linkers for ADC Development: A Buyer’s Guide

The linker you choose can make or break an antibody-drug conjugate. Cleavable linkers — designed to release their cytotoxic payload only inside the target cell — are the backbone of most clinically approved ADCs, from Adcetris to Enhertu. But with hundreds of cleavable PEG linker variants now on the market, selecting the right one for your conjugation strategy, payload, and development stage is a real challenge. This buyer’s guide ranks the 10 best cleavable PEG linkers available today, covering enzyme-cleavable Val-Cit and GGFG dipeptide/tetrapeptide systems, acid-labile hydrazones, and redox-sensitive disulfide linkers. Whether you’re a medicinal chemist screening payloads in early discovery or a procurement manager sourcing GMP-ready linker-payloads, this guide will help you compare options, understand trade-offs, and make a confident purchasing decision.

What to Look For When Buying Cleavable PEG Linkers

Before diving into specific products, keep these five criteria in mind. They separate a linker that performs in the lab from one that derails a program six months down the road.

1. Cleavage Mechanism and Selectivity

The most common enzyme-cleavable motif is the valine-citrulline (Val-Cit) dipeptide recognized by cathepsin B, a lysosomal protease overexpressed in many tumor types. Tetrapeptide sequences like GGFG offer alternative cleavage kinetics. Acid-cleavable linkers (hydrazones, acetals) exploit the low pH of endosomes and lysosomes, while disulfide linkers rely on intracellular glutathione concentrations. Match the mechanism to your target biology: cathepsin-rich tumors favor Val-Cit, whereas targets with poor lysosomal trafficking may benefit from acid- or redox-triggered release.

2. PEG Spacer Length and Dispersity

The PEG spacer between the conjugation handle and the cleavable motif directly impacts aqueous solubility, pharmacokinetics, and drug-to-antibody ratio (DAR) homogeneity. Monodisperse PEG (discrete, single-molecular-weight chains like PEG4 or PEG8) gives you a defined molecular entity with a single peak on LC-MS — critical for analytical characterization, IND-enabling studies, and regulatory filings. Polydisperse PEG, by contrast, introduces batch-to-batch variability that complicates QC. Always verify whether a supplier provides monodisperse or polydisperse material.

3. Conjugation Handle Compatibility

Your linker must match your antibody engineering strategy. Maleimide handles conjugate to engineered cysteines (the classic approach). Amine-reactive NHS esters target lysines. Click chemistry handles — azide, DBCO, and BCN — enable site-specific conjugation via strain-promoted azide-alkyne cycloaddition (SPAAC), producing more homogeneous ADCs with predictable DAR profiles. Evaluate which handles align with your existing antibody platform before locking in a linker.

4. Purity and Analytical Documentation

For any compound that will enter in vivo studies, you need ≥95% purity at minimum — and ≥99% is strongly preferred. Request HPLC traces, mass spectrometry data, and certificates of analysis. Suppliers who routinely provide this documentation save you weeks of qualification work. For a deeper dive into how linker chemistry impacts stability and payload release, see PurePEG’s technical overview on linker chemistry, ADC stability, and solubility.

5. Supply Reliability and Custom Synthesis

ADC programs run on tight timelines. A linker that’s perpetually backordered — or only available from a single overseas source — introduces program risk. Prioritize suppliers with domestic inventory, fast shipping, and the synthetic capability to produce custom PEG lengths or alternative payloads when your program evolves.

—

The 10 Best Cleavable PEG Linkers for ADC Development

1. PurePEG Mal-PEG8-Val-Cit-PAB-MMAE

Best for: Cysteine-conjugated ADCs requiring optimized hydrophilicity

The gold standard for cathepsin-cleavable ADC construction. This monodisperse linker-payload combines a maleimide conjugation handle with a PEG8 spacer, a Val-Cit cleavable dipeptide, a self-immolative PAB (para-aminobenzyloxycarbonyl) group, and the potent antimitotic payload MMAE. The extended PEG8 chain provides superior aqueous solubility compared to shorter-chain alternatives, reducing aggregation at higher DAR values — a persistent challenge in ADC manufacturing.

PurePEG synthesizes this compound in-house at their San Diego facility with 99%+ purity and full analytical documentation (HPLC, MS, NMR). With 1,433 Bioz citations across PurePEG’s catalog and linker-payload products used in FDA-approved ADC programs, this is a supplier with a proven regulatory track record. CAS: 2353409-69-3.

Key specs: Monodisperse PEG8 | Maleimide conjugation | Cathepsin B cleavage | MMAE payload | ≥99% purity

→ View Mal-PEG8-Val-Cit-PAB-MMAE on PurePEG

—

2. PurePEG Amino-PEG4-Val-Cit-PAB-MMAE

Best for: Amine-coupling strategies and NHS-ester-based bioconjugation

When your conjugation chemistry requires an amine handle rather than a maleimide, this linker-payload delivers. The free amino group can be coupled to NHS-ester-activated antibodies, carboxylic acid-functionalized surfaces, or used as an intermediate in multi-step conjugation workflows. The PEG4 spacer provides a good balance of solubility and molecular weight, while the Val-Cit-PAB-MMAE module provides the same proven cleavage-and-release mechanism used in brentuximab vedotin (Adcetris).

At $621–$1,118 depending on quantity, this product offers competitive pricing for a monodisperse, analytically characterized linker-payload — particularly compared to custom synthesis quotes from CROs. CAS: 1492056-71-9.

Key specs: Monodisperse PEG4 | Free amine handle | Cathepsin B cleavage | MMAE payload | ≥99% purity

→ View Amino-PEG4-Val-Cit-PAB-MMAE on PurePEG

—

3. PurePEG Azido-PEG4-Val-Cit-PAB-MMAE

Best for: Site-specific ADCs via click chemistry (SPAAC)

Click chemistry has transformed ADC development by enabling site-specific conjugation with exceptional DAR homogeneity. This azide-functionalized linker-payload is designed for strain-promoted azide-alkyne cycloaddition (SPAAC) with DBCO- or BCN-modified antibodies — no copper catalyst required, preserving antibody integrity. The result is a more homogeneous ADC with a defined DAR, improving both efficacy and therapeutic index.

The monodisperse PEG4 spacer ensures a single molecular species on mass spec, simplifying analytical characterization during development. PurePEG provides this compound with full QC documentation and ships from their San Diego facility, typically within one business day. For guidance on selecting the right linker architecture for your program, see PurePEG’s ADC linker selection guide. CAS: 1869126-64-6. Priced at $998–$1,398.

Key specs: Monodisperse PEG4 | Azide handle (click-ready) | Cathepsin B cleavage | MMAE payload | ≥99% purity

→ View Azido-PEG4-Val-Cit-PAB-MMAE on PurePEG

—

4. PurePEG DBCO-PEG4-Val-Cit-PAB-MMAF

Best for: Click conjugation with a non-permeable payload for reduced bystander toxicity

This linker-payload pairs a DBCO click handle with the cell-impermeable payload MMAF instead of MMAE. Why does that matter? MMAF’s charged C-terminal phenylalanine prevents it from diffusing across cell membranes after release, virtually eliminating bystander killing of antigen-negative neighboring cells. This makes DBCO-PEG4-Val-Cit-PAB-MMAF the preferred choice for targets expressed on tumors adjacent to sensitive normal tissues.

The DBCO group reacts with azide-modified antibodies via copper-free SPAAC, and the monodisperse PEG4 spacer maintains solubility without adding unnecessary molecular weight. At $960, this is a cost-effective entry point for programs exploring MMAF-based ADCs with site-specific conjugation. CAS: 2244602-23-9.

Key specs: Monodisperse PEG4 | DBCO handle (click-ready) | Cathepsin B cleavage | MMAF payload (non-permeable) | ≥99% purity

→ View DBCO-PEG4-Val-Cit-PAB-MMAF on PurePEG

—

5. PurePEG endo-BCN-PEG4-Val-Cit-PAB-MMAE

Best for: Ultra-fast click conjugation with superior reaction kinetics

Bicyclononyne (BCN) is an increasingly popular alternative to DBCO for SPAAC click chemistry. The endo-BCN isomer reacts with azides significantly faster than exo-BCN, enabling shorter conjugation times and higher conversion rates — a practical advantage when working with precious antibody material. This linker-payload brings that kinetic advantage to a full Val-Cit-PAB-MMAE cleavable system.

Like all PurePEG products, this compound is monodisperse (discrete PEG4), synthesized at ≥99% purity, and backed by complete analytical data. PurePEG’s catalog includes 199 cleavable linker products, so if your program requires a different PEG length or payload, custom variants are readily available. Priced at $796–$1,195.

Key specs: Monodisperse PEG4 | endo-BCN handle (fast click kinetics) | Cathepsin B cleavage | MMAE payload | ≥99% purity

→ View endo-BCN-PEG4-Val-Cit-PAB-MMAE on PurePEG

—

6. MedChemExpress MC-Val-Cit-PAB-MMAE

Best for: Budget-friendly screening in early discovery

MedChemExpress’s MC-Val-Cit-PAB-MMAE is one of the most widely cited cleavable linker-payloads in academic ADC research. The maleimidocaproyl (MC) handle conjugates to cysteine residues, and the Val-Cit-PAB-MMAE cassette mirrors the cleavage mechanism of Adcetris. It’s a solid workhorse for initial screening when you need to test multiple constructs quickly and affordably.

The trade-off: the MC spacer is a simple alkyl chain rather than a PEG spacer, which means reduced hydrophilicity at higher DAR values. Additionally, standard commercial-grade material is typically polydisperse or provided without the rigorous monodispersity guarantees offered by specialized PEG suppliers. For programs advancing beyond hit identification, upgrading to a monodisperse PEG-spaced variant (like those from PurePEG) is strongly recommended.

Key specs: MC (alkyl) spacer | Maleimide conjugation | Cathepsin B cleavage | MMAE payload | Typically ≥95% purity

—

7. BroadPharm Azido-PEG-Val-Cit-PAB

Best for: Modular linker construction (add your own payload)

BroadPharm offers azide-terminated Val-Cit-PAB linkers across multiple PEG lengths (PEG2 through PEG12), giving researchers flexibility to optimize spacer length for a given antibody-target pair. Crucially, these are linker-only constructs — no payload attached — which allows teams to conjugate their own proprietary or novel cytotoxic agents downstream.

This modular approach is appealing for discovery-stage programs testing unconventional payloads, but it adds a synthesis step (payload attachment and purification) that ready-to-use linker-payloads like PurePEG’s products eliminate. Verify whether BroadPharm’s PEG is monodisperse for your specific length, as longer PEG chains from some suppliers may be polydisperse blends.

Key specs: Various PEG lengths | Azide handle | Cathepsin B cleavage | No payload (modular) | Purity varies by catalog number

—

8. Concortis/Levena MC-GGFG-MMAE

Best for: Programs requiring alternative protease-cleavable sequences

The Gly-Gly-Phe-Gly (GGFG) tetrapeptide is a cathepsin-cleavable sequence that offers distinct cleavage kinetics compared to the standard Val-Cit dipeptide. Some tumor types show enhanced payload release with GGFG, and the tetrapeptide motif has appeared in next-generation ADC candidates exploring differentiated pharmacology. Concortis (now part of the Levena Biopharma portfolio) supplies MC-GGFG-MMAE as a ready-to-conjugate linker-payload.

This is a niche option best suited for teams that have already evaluated Val-Cit and are exploring alternative cleavage kinetics in head-to-head studies. Note that the MC spacer, like the MedChemExpress product above, lacks the hydrophilicity benefits of a PEG spacer — a factor worth considering if aggregation has been an issue in your program.

Key specs: MC (alkyl) spacer | Maleimide conjugation | Cathepsin B cleavage (GGFG tetrapeptide) | MMAE payload | ≥95% purity

—

9. Creative Biolabs pH-Sensitive Hydrazone Linkers

Best for: Targets with limited cathepsin B expression

Not every tumor target is well-served by enzyme-cleavable linkers. pH-sensitive linkers — particularly hydrazones — exploit the acidic environment of endosomes (pH ~5.0–6.0) and lysosomes (pH ~4.5–5.0) to trigger payload release, bypassing the need for specific protease activity entirely. Creative Biolabs offers a panel of acid-cleavable linker constructs for custom ADC development.

The caveat: hydrazone linkers historically suffer from lower plasma stability compared to Val-Cit dipeptides, leading to premature payload release and off-target toxicity. Gemtuzumab ozogamicin (Mylotarg) used a hydrazone linker and was temporarily withdrawn from market partly due to toxicity concerns. Modern designs have improved stability, but acid-cleavable linkers require more extensive in vivo validation. For a strategic framework on balancing stability and release, see PurePEG’s guide on cleavable linker selection.

Key specs: Hydrazone (acid-cleavable) | Various conjugation handles | pH-triggered release | Custom payloads | Purity varies

—

10. CellMosaic Disulfide PEG Linkers

Best for: Intracellular glutathione-triggered release in redox-rich tumors

Disulfide linkers represent a third cleavage mechanism: they are reduced by the high intracellular glutathione concentrations (1–10 mM) found inside cells, compared to the much lower levels (~5 μM) in plasma. CellMosaic offers PEG-based disulfide linkers that can be conjugated to thiol-bearing payloads and antibodies. The PEG spacer adds solubility, addressing one of the traditional drawbacks of disulfide-linked ADCs.

Disulfide linkers offer decent plasma stability when sterically hindered (e.g., with geminal dimethyl groups flanking the disulfide bond), but their cleavage is less tumor-selective than enzyme-triggered mechanisms — any cell with high glutathione levels can reduce the bond. This limits the therapeutic window compared to Val-Cit-based systems. They are most appropriate for specific research applications or as orthogonal controls in linker screening panels.

Key specs: PEG-disulfide | Thiol conjugation | Glutathione-triggered cleavage | Various payloads | Purity varies

—

How to Choose the Right Cleavable PEG Linker

With ten strong options on the table, here’s how to narrow the field based on your program’s specific needs.

By Conjugation Strategy

By Development Stage

• Early discovery / screening: Start with #6 (MCE MC-Val-Cit-PAB-MMAE) for cost-effective screening, then transition to PurePEG’s monodisperse products (#1–#5) when you have a lead candidate.
• Lead optimization: PurePEG products #1–#5 give you the analytical clarity (single species on MS) and purity (≥99%) needed for in vivo PK/PD studies and IND-enabling work.
• Late-stage / GMP-track: Monodisperse PEG with full CoA documentation is essential. PurePEG’s FDA-approved ADC heritage and custom synthesis capability make them a strong partner for late-stage supply.

By Cleavage Mechanism

• Cathepsin B (enzyme-cleavable): Products #1–#8 — the most clinically validated mechanism. Val-Cit (#1–#7) is the default; consider GGFG (#8) only if Val-Cit shows suboptimal cleavage for your target.
• Acid-cleavable: Product #9 — use when cathepsin expression is low or intracellular trafficking bypasses lysosomes.
• Redox-cleavable: Product #10 — niche application; best as an orthogonal mechanism in comparative studies.

MMAE vs. MMAF Payloads

If bystander killing of neighboring antigen-negative cells is desirable (heterogeneous tumors), choose MMAE-based linkers (#1, #2, #3, #5). If bystander toxicity is a concern (targets near sensitive tissues), choose the MMAF variant (#4), whose charged structure prevents membrane permeation after release.

—

Frequently Asked Questions

What is a cleavable linker in ADC development?

A cleavable linker is the chemical bridge between an antibody and its cytotoxic payload that is designed to break apart under specific intracellular conditions — typically enzyme activity (cathepsin B), acidic pH (endosomal/lysosomal), or reducing environments (glutathione). This controlled release ensures the drug is activated primarily inside target cells, maximizing tumor-killing efficacy while minimizing systemic toxicity. The Val-Cit dipeptide is the most widely used cleavable motif in FDA-approved ADCs.

Why do monodisperse PEG linkers matter for ADCs?

Monodisperse PEG linkers consist of a single, defined chain length (e.g., exactly PEG4 or PEG8), unlike polydisperse PEGs, which are mixtures of varying chain lengths. For ADCs, monodispersity means every linker-payload molecule is identical, producing a single species on mass spectrometry. This simplifies analytical characterization, improves batch-to-batch reproducibility, and streamlines regulatory documentation — all critical factors as a program moves from discovery toward IND filing and clinical trials.

How do I choose between Val-Cit and other cleavable motifs?

Val-Cit is the default starting point for most ADC programs because it has the strongest clinical validation (used in Adcetris and multiple other approved ADCs). Consider alternatives like the GGFG tetrapeptide if your target’s cathepsin B levels are low and a different protease profile may improve release kinetics. Acid-cleavable (hydrazone) and redox-cleavable (disulfide) linkers are best reserved for targets where enzyme-mediated cleavage is unreliable, though they generally offer a narrower therapeutic window.

Can I get custom PEG lengths or alternative payloads?

Yes. Suppliers like PurePEG offer custom synthesis services, allowing you to specify exact PEG lengths (PEG2 through PEG24+), swap payloads (MMAE, MMAF, exatecan, DXd, and others), or modify conjugation handles. PurePEG’s catalog already includes 199 cleavable linker products, and their San Diego-based synthesis team can produce custom variants for programs with specialized requirements.

—

Ready to Source Your Cleavable Linkers?

PurePEG’s complete cleavable linker catalog includes 199 monodisperse products spanning Val-Cit, GGFG, and other cleavable motifs with every major conjugation handle and payload combination. Every product ships with 99%+ purity, full analytical documentation, and next-day dispatch from San Diego.

Whether you’re building your first ADC construct or scaling a clinical candidate, start with the linkers trusted in FDA-approved programs.

→ Browse All Cleavable Linkers at PurePEG